Overview

To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.

Status:
Unknown status

Trial end date:
2021-04-03

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy beyond progression of vemurafenib combined with cobimetinib associated with local treatment compared to second-line treatment in patients with BRAFV600 mutation-positive metastatic melanoma in focal progression with first-line combined vemurafenib and cobimetinib.

Phase:

Phase 2

Details

Lead Sponsor:

Intergruppo Melanoma Italiano

Treatments:

Nivolumab
Pembrolizumab
Vemurafenib